Matrix Partners

Matrix Partners is a long-running early-stage firm with US offices in Cambridge and San Francisco and historically separate Indian and Chinese affiliates (Matrix India and Matrix China, the latter rebranded as MPCi), each operating with its own fund and partnership but sharing a brand and a thesis lineage. The firm has produced category leaders including HubSpot, Apple (at founding), Zendesk, Oculus, Quora, and a long list of enterprise and consumer winners. For healthcare and AI founders, Matrix has been a selective healthcare investor, with the US partnership making bets in healthcare technology, clinical software, and care-delivery software where the founder profile and technical wedge fit, and the Indian partnership having a deeper healthcare practice that has backed several digital health and Indian healthcare-services companies. The firm’s AI activity in the post-2022 cycle has been measured rather than aggressive; Matrix is a thesis-driven early-stage firm that does not chase momentum rounds, and the AI deals it has done have generally been in foundational infrastructure or differentiated applications rather than thinly-differentiated wrappers. Stage focus is seed and Series A, with check sizes in the two-to-fifteen-million range and a strong reserve posture for follow-ons through Series B. Matrix does not have a growth fund and will not lead later rounds, so founders should plan to bring in a multi-stage partner as the company scales. Geography is US-focused for the US fund, with explicit India coverage through Matrix India and limited China activity through MPCi; the US fund operates between Cambridge and San Francisco and invests across the country. Founders who should approach Matrix are early-stage technical or product founders with a clear category thesis and a partner-quality match; Matrix partners (Antonio Rodriguez, Dana Stalder, Stan Reiss, and others) tend to invest in fewer companies per year than partners at larger firms and to be highly engaged with each one, so the partnership fit matters more than the firm’s brand. Healthcare founders specifically should approach Matrix if they are building software-economics businesses with a defensible product wedge; founders building therapeutics, devices, or services-heavy care delivery should look elsewhere. The entry path that works best is a partner-specific intro through a portfolio CEO or a known Matrix-affiliated operator; cold inbound to Matrix has a lower conversion than at platform-style firms because the partnership is small and intentionally so. When you pitch, lead with the team’s reason to believe and the smallest piece of evidence that the thesis is correct; Matrix partners decide on conviction, not on consensus, and they will engage deeply once a partner picks up the deal. Caveats: Matrix is intentionally small and not a platform firm, so the value-add is the partner’s time and network rather than back-office services; the US and Indian funds operate separately, so a deal that fits Matrix India will not be picked up by the US fund and vice versa; valuations are market for the stage; governance includes board seats and active involvement; and the firm has gone through partner-roster changes in recent years, so reference-call the specific partner you are targeting before signing.